Ontario Teachers Pension Plan Board Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ontario Teachers Pension Plan Board trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 22.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,098 shares of the specialty pharmaceutical company’s stock after selling 2,083 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Jazz Pharmaceuticals were worth $791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after acquiring an additional 84,941 shares in the last quarter. Covestor Ltd raised its position in shares of Jazz Pharmaceuticals by 107.4% in the first quarter. Covestor Ltd now owns 618 shares of the specialty pharmaceutical company’s stock worth $74,000 after acquiring an additional 320 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 9.2% during the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company’s stock worth $1,171,000 after acquiring an additional 819 shares in the last quarter. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at about $171,943,000. Finally, Estuary Capital Management LP increased its stake in shares of Jazz Pharmaceuticals by 67.2% in the 1st quarter. Estuary Capital Management LP now owns 213,450 shares of the specialty pharmaceutical company’s stock valued at $25,704,000 after purchasing an additional 85,779 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 4.9 %

Shares of JAZZ stock opened at $125.10 on Friday. The company has a 50-day moving average of $112.92 and a two-hundred day moving average of $110.52. The firm has a market cap of $7.56 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,110 shares of company stock valued at $720,160. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on JAZZ shares. TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $163.00 price target (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, Wells Fargo & Company cut their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.